These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39015574)

  • 1. A novel approach with tofacitinib for the management of keratoderma blennorrhagicum in reactive arthritis: a case report.
    Maitiyaer M; Liu Y; Keyimu N; Wen Y; Liu Z; Huang W; Yu S
    Front Immunol; 2024; 15():1399249. PubMed ID: 39015574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful use of tofacitinib in reactive arthritis refractory to conventional therapies - a case series.
    Maikap D; Padhan P
    Mod Rheumatol Case Rep; 2022 Jun; 6(2):167-170. PubMed ID: 35024869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
    Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
    Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib for treatment of rheumatoid arthritis.
    Rakieh C; Conaghan PG
    Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
    Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
    Front Immunol; 2021; 12():738481. PubMed ID: 34630419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
    Burgos-Vargas R; Cardiel M; Xibillé D; Pacheco-Tena C; Pascual-Ramos V; Abud-Mendoza C; Mahgoub E; Rahman M; Fan H; Rojo R; García E; Santana K
    Reumatol Clin (Engl Ed); 2019; 15(1):43-53. PubMed ID: 28552437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.
    Koga T; Sato T; Umeda M; Fukui S; Horai Y; Kawashiri SY; Iwamoto N; Ichinose K; Nakamura H; Kawakami A
    Clin Immunol; 2016 Dec; 173():147-148. PubMed ID: 27720846
    [No Abstract]   [Full Text] [Related]  

  • 12. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
    Kawalec P; Mikrut A; Wiśniewska N; Pilc A
    Clin Rheumatol; 2013 Oct; 32(10):1415-24. PubMed ID: 23877486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
    Iwata S; Tanaka Y
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.
    Scott LJ
    Drugs; 2013 Jun; 73(8):857-74. PubMed ID: 23716132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
    Miserocchi E; Giuffrè C; Cornalba M; Pontikaki I; Cimaz R
    Clin Rheumatol; 2020 Mar; 39(3):847-851. PubMed ID: 31897953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
    Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Graham D; Wang C; Cappelleri JC; Hendrikx T; Hsu MA
    RMD Open; 2019; 5(1):e000806. PubMed ID: 30713721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAPHO Syndrome Complicated by Ankylosing Spondylitis Successfully Treated With Tofacitinib: A Case Report.
    Yuan F; Luo J; Yang Q
    Front Immunol; 2022; 13():911922. PubMed ID: 35693775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The off-label uses profile of tofacitinib in systemic rheumatic diseases.
    Zhao Z; Ye C; Dong L
    Int Immunopharmacol; 2020 Jun; 83():106480. PubMed ID: 32283509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.